Efficacy of HIFU-AR on Blood Loss Reduction in Patients With Liver Metastases Requiring Hepatectomy

Inclusion Criteria: * Age ≥ 18 years at the day of consenting to the study. * Patients with liver metastases requiring a hepatectomy for ≥ 2 segments. * ECOG PS ≤ 1. * Adequate bone marrow and liver function at baseline as defined below: * Platelet count ≥ 100 x 109/l, and hemoglobin of ≥ 9 g/dl), * Total bilirubin ≤ 1.5 x ULN, AST and ALT ≤ 5 x ULN. * Recovered from prior anti-neoplasic treatment-related toxicity (grade \<2 persistent treatment-related toxicity as per CTCAE v4 are accepted). * Willingness for follow-up visits. * Covered by a medical insurance. * Signed and dated informed consent document indicating that the patient has been informed of all aspects of the trial prior to enrolment. Exclusion Criteria: * Patients having previously undergone * a major hepatic surgery (i.e. more than 3 liver segments) or * biliary major surgery. * Patient with cirrhosis or sinusoidal obstruction syndrome with portal hypertension. * Pregnant women (women of childbearing potential are required to have a negative pregnancy test within 72 hours prior to inclusion). A positive urine test must be confirmed by a serum pregnancy test.